NCT04700514

Brief Summary

This study evaluate the effect of dexmedetomidine on intelligence test in pediatric patients with multiple anesthesia exposure. Children who are diagnosed with retinoblastoma and receive first exam under general anesthesia before age of 2 are included. Intelligence test will performed when patients' age are 4.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Feb 2021

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 4, 2021

Completed
4 days until next milestone

First Posted

Study publicly available on registry

January 8, 2021

Completed
28 days until next milestone

Study Start

First participant enrolled

February 5, 2021

Completed
4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 20, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

February 20, 2025

Completed
Last Updated

April 24, 2023

Status Verified

April 1, 2023

Enrollment Period

4 years

First QC Date

January 4, 2021

Last Update Submit

April 21, 2023

Conditions

Outcome Measures

Primary Outcomes (2)

  • IQ score at age of 4

    Korean-Wechsler Preschool and Primary Scale of Intelligence test (score \>131, high; score 116-130, high-normal; socre 85-115, normal; score 70-84; low-normal; score \<69; low)

    year 4

  • Developmental Test

    visual-Motor Integration test

    year 4

Study Arms (2)

Control group

NO INTERVENTION

1. Children diagnosed with retinoblastoma and received exam under anesthesia (EUA) before the age of 30 months, and is not yet 4 years old 2. Children who are undergoing exams and treatment such as EUA, chemoport insertion, or intra-arterial chemotherapy under general anesthesia 3. Sevoflurane is used only for anesthesia

Dexmedetomidine group

EXPERIMENTAL

1. Children who are diagnosed with retinoblastoma and are scheduled for the first EUA before their age of 30 months. 2. No history of anesthesia

Drug: Dexmedetomidine

Interventions

Dexmedetomidine (1 mcg/kg loading for 10 min, then 1 mcg/kg/min continuous infusion) is used with sevoflurane in every time of general anesthesia

Dexmedetomidine group

Eligibility Criteria

AgeUp to 2 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Patients who are first diagnosed as retinoblastoma and scheduled for EUA and treatment under general anesthesia before age of 2

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Seoul National University Hospital

Seoul, 03080, South Korea

RECRUITING

MeSH Terms

Conditions

Retinoblastoma

Interventions

Dexmedetomidine

Condition Hierarchy (Ancestors)

Neoplasms, NeuroepithelialNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasmsNeoplasms, Glandular and EpithelialNeoplasms, Nerve TissueRetinal NeoplasmsEye NeoplasmsNeoplasms by SiteEye Diseases, HereditaryEye DiseasesRetinal Diseases

Intervention Hierarchy (Ancestors)

ImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Central Study Contacts

Ji-Hyun Lee, MD, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Associate Professor

Study Record Dates

First Submitted

January 4, 2021

First Posted

January 8, 2021

Study Start

February 5, 2021

Primary Completion

January 20, 2025

Study Completion

February 20, 2025

Last Updated

April 24, 2023

Record last verified: 2023-04

Locations